PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

PharmaCyte Biotech, Inc.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026

$0.34+0.00 (+0.53%)

Close on Oct 19, 2026

Market cap: $3.67M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jul 31, 2026

PharmaCyte Biotech reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in PharmaCyte Biotech's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in PharmaCyte Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-1500 reverse split on Aug 10, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PMCB.

Company	Revenue	Growth
CRDF	$508.00K	-7.0%
PMCB	$0	–
CLDI	–	–
GNTA	–	–
AURA	–	–
CERO	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: April 30
Employees: 2
Held by institutions: 7.1%
Auditor: CBIZ CPAs P.C
SEC CIK: 1157075

Advertisement
300 × 250